Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia
Leading schizophrenia
Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
New hope emerges for treatment-resistant schizophrenia: leading KOLs to reveal insights into the
SAVE THE DATE
June 25, 2024
Evenamide: Roadmap to Registration
Investor Day 2024
Join us for a deep dive into the unmet needs and new concepts for treating poor responders and
Ad hoc announcement pursuant to Art. 53 LR
Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings
Ad hoc announcement pursuant to Art. 53 LR
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, April 17, 2024, 11:30 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year
Presentation of study
Dear Newron Shareholder,
when presenting our Annual Report 2023, recently, we looked back at the significant progress Newron has made, last year: against a backdrop of challenging
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.